Regenyx Medical
Regenyx is redefining soft tissue restoration with matrix-enhanced fat grafting
Company Overview
Snapshot
Founded in November 2016 by Yaron Rapaport and Prof. Hanna Rapaport, Regenyx Medical operates with 1–10 employees. The company has raised $3.4 million across three funding rounds from two investors. In June 2025, Regenyx Medical was selected for the MedTech Innovator and ASPS Top 5 Innovation Track.
Business overview
Regenyx Medical is focused on redefining minimally invasive soft tissue restoration, a critical area within plastic and reconstructive surgery. The company's core product, Lipogenyx, is a next-generation fat grafting solution designed to enhance graft survival and integration, leading to natural-looking, lasting, and predictable results in reconstructive and aesthetic procedures. Built on a proprietary synthetic peptide hydrogel technology, Lipogenyx aims to provide a scalable and potentially reimbursable platform that reduces the need for revision fat grafting procedures, improving physician efficiency and patient satisfaction. Regenyx Medical operates within the Health Tech & Life Sciences sector, specifically targeting Pharma & Medical Biotechnology, Biomaterials & Tissue Engineering, and Drug Delivery markets globally.
Strategic signal
In June 2025, Regenyx Medical was recognized by its selection for both the MedTech Innovator and ASPS Top 5 Innovation Track. This dual recognition signals strong industry validation for the company's Lipogenyx product, highlighting its potential to disrupt soft tissue restoration with its proprietary synthetic peptide hydrogel technology. For investors, this indicates significant progress in market acceptance and a clear path towards clinical studies and U.S. operations, positioning Regenyx Medical as a promising innovator in the medical technology landscape.
Log in to access full profile ›Company Intelligence Q&A
- What is Regenyx Medical's primary focus?
- Regenyx Medical focuses on redefining minimally invasive soft tissue restoration, particularly in plastic and reconstructive surgery, with its matrix-enhanced fat grafting technology.
- When was Regenyx Medical founded?
- Regenyx Medical was founded in November 2016.
- What is Lipogenyx?
- Lipogenyx is Regenyx Medical's lead product, a fat viability extender that enhances graft survival and integration for natural-looking, lasting, and predictable results in reconstructive and aesthetic procedures.
- Has Regenyx Medical received any recent industry recognition?
- In June 2025, Regenyx Medical was selected for the MedTech Innovator and ASPS Top 5 Innovation Track, recognizing its breakthrough medical technology.
- Which investors participated in Regenyx Medical's May 2019 funding round?
- In May 2019, Regenyx Medical received funding from the Israel Innovation Authority.